DRUG · Mapped RxNorm record
Eribulin Mesylate
Normalized identity: eribulin mesylateView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
NCT01908101
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
Laboratory Biomarker Analysis
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedEribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Recurrent Breast Carcinomaunresolved
Stage IV Breast Cancerunresolved
Interventions
Eribulin MesylateDRUG · verified · RxNorm: eribulin mesylate
Sponsors & collaborators
University of Washingtonlead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01908101 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.